Study of Cancer and Immune Cell Metabolism Affecting Treatment Outcomes in Adults With Blood Cancers

What this Trial Is About

Researchers are studying how the metabolism of cancer and immune cells affects the bone marrow environment, therapy resistance, and outcomes in blood cancers such as acute myeloid leukemia AML, myelodysplastic syndrome MDS, and myelofibrosis. These cancers often require chemotherapy and stem cell transplants, but relapse remains common. Understanding metabolic interactions in the bone marrow could lead to new treatment strategies. The study observes participants with hematological cancers and healthy stem cell donors to analyze metabolic processes. It involves detailed profiling of metabolites, lipids, gene expression, and metabolic function at multiple points at diagnosis, after chemotherapy, before stem cell transplant, and up to one year post-transplant, including at relapse if it occurs. This observational research aims to uncover critical metabolic pathways influencing disease progression and treatment response. Participants will undergo regular assessments including blood and bone marrow sampling for metabolic and molecular analysis. Researchers will track treatment responses, progression-free survival, and overall survival for up to five years after transplant. The study collects data at various timepoints to monitor how metabolism changes over the course of treatment and disease, aiming to improve understanding and guide personalized therapies in hematologic cancers.

Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies